🚀 VC round data is live in beta, check it out!
Innovent Biologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Innovent Biologics and similar public comparables like Genmab, Viatris, Shionogi, Sichuan Biokin and more.
Innovent Biologics Overview
About Innovent Biologics
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt’s main competition include drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Meyers.
Founded
2011
HQ
Employees
5.7K
Website
Sectors
Financials (LTM)
EV
$17B
Innovent Biologics Financials
Innovent Biologics reported last 12-month revenue of $2B and EBITDA of $254M.
In the same LTM period, Innovent Biologics generated $2B in gross profit, $254M in EBITDA, and $182M in net income.
Revenue (LTM)
Innovent Biologics P&L
In the most recent fiscal year, Innovent Biologics reported revenue of $1B and EBITDA of $59M.
Innovent Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $254M | XXX | $59M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 4% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $182M | XXX | ($14M) | XXX | XXX | XXX |
| Net Margin | 9% | XXX | (1%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Innovent Biologics Stock Performance
Innovent Biologics has current market cap of $18B, and enterprise value of $17B.
Market Cap Evolution
Innovent Biologics' stock price is $10.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17B | $18B | -0.1% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInnovent Biologics Valuation Multiples
Innovent Biologics trades at 8.9x EV/Revenue multiple, and 67.9x EV/EBITDA.
EV / Revenue (LTM)
Innovent Biologics Financial Valuation Multiples
As of March 31, 2026, Innovent Biologics has market cap of $18B and EV of $17B.
Equity research analysts estimate Innovent Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Innovent Biologics has a P/E ratio of 99.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBITDA | 67.9x | XXX | 291.7x | XXX | XXX | XXX |
| EV/EBIT | 88.9x | XXX | 461.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.3x | XXX | 15.1x | XXX | XXX | XXX |
| P/E | 99.5x | XXX | (1325.5x) | XXX | XXX | XXX |
| EV/FCF | 28.6x | XXX | (285.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Innovent Biologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Innovent Biologics Margins & Growth Rates
Innovent Biologics' revenue in the last 12 month grew by 42%.
Innovent Biologics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Innovent Biologics' rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Innovent Biologics' rule of X is 149% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Innovent Biologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 103% | XXX | 222% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 70% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 149% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 47% | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Innovent Biologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genmab | XXX | XXX | XXX | XXX | XXX | XXX |
| Viatris | XXX | XXX | XXX | XXX | XXX | XXX |
| Shionogi | XXX | XXX | XXX | XXX | XXX | XXX |
| Sichuan Biokin | XXX | XXX | XXX | XXX | XXX | XXX |
| Incyte | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innovent Biologics M&A Activity
Innovent Biologics acquired XXX companies to date.
Last acquisition by Innovent Biologics was on XXXXXXXX, XXXXX. Innovent Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Innovent Biologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInnovent Biologics Investment Activity
Innovent Biologics invested in XXX companies to date.
Innovent Biologics made its latest investment on XXXXXXXX, XXXXX. Innovent Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Innovent Biologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Innovent Biologics
| When was Innovent Biologics founded? | Innovent Biologics was founded in 2011. |
| Where is Innovent Biologics headquartered? | Innovent Biologics is headquartered in China. |
| How many employees does Innovent Biologics have? | As of today, Innovent Biologics has over 5K employees. |
| Who is the CEO of Innovent Biologics? | Innovent Biologics' CEO is De-Chao Michael Yu. |
| Is Innovent Biologics publicly listed? | Yes, Innovent Biologics is a public company listed on HKEX. |
| What is the stock symbol of Innovent Biologics? | Innovent Biologics trades under 01801 ticker. |
| When did Innovent Biologics go public? | Innovent Biologics went public in 2018. |
| Who are competitors of Innovent Biologics? | Innovent Biologics main competitors are Genmab, Viatris, Shionogi, Sichuan Biokin. |
| What is the current market cap of Innovent Biologics? | Innovent Biologics' current market cap is $18B. |
| What is the current revenue of Innovent Biologics? | Innovent Biologics' last 12 months revenue is $2B. |
| What is the current revenue growth of Innovent Biologics? | Innovent Biologics revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Innovent Biologics? | Current revenue multiple of Innovent Biologics is 8.9x. |
| Is Innovent Biologics profitable? | Yes, Innovent Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Innovent Biologics? | Innovent Biologics' last 12 months EBITDA is $254M. |
| What is Innovent Biologics' EBITDA margin? | Innovent Biologics' last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Innovent Biologics? | Current EBITDA multiple of Innovent Biologics is 67.9x. |
| What is the current FCF of Innovent Biologics? | Innovent Biologics' last 12 months FCF is $602M. |
| What is Innovent Biologics' FCF margin? | Innovent Biologics' last 12 months FCF margin is 31%. |
| What is the current EV/FCF multiple of Innovent Biologics? | Current FCF multiple of Innovent Biologics is 28.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.